Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lonidamine

Next Previous
Drug Profile

Lonidamine

Alternative Names: TH-070

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Threshold Pharmaceuticals
  • Class Cytostatics; Indazoles; Small molecules
  • Mechanism of Action Glycolysis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 04 Sep 2006 Interim results from discontinued phase II and phase III clinical trials in patients with benign prostatic hyperplasia have been added to the adverse events and Mens Health therapeutic trials sections
  • 17 Jul 2006 Discontinued - Phase-II for Benign prostatic hyperplasia in Italy (PO)
  • 17 Jul 2006 Discontinued - Phase-II for Benign prostatic hyperplasia in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top